Rigel Pharmaceuticals [NASDAQ: RIGL] price plunged by -1.32 percent to reach at -$0.02. The one-year RIGL stock forecast points to a potential upside of 75.49. The average equity rating for RIGL stock is currently 2.33, trading closer to a bullish pattern in the stock market.
Rigel Pharmaceuticals [NASDAQ: RIGL] price plunged by -2.33 percent to reach at -$0.03. The company report on April 4, 2024 at 8:05 AM that Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma. Olutasidenib induced
Rigel Pharmaceuticals [NASDAQ: RIGL] gained 5.41% or 0.08 points to close at $1.56 with a heavy trading volume of 3436162 shares. The daily chart for RIGL points out that the company has recorded 36.84% gains over the past six months. If we look at the
© 2024, Powered by Smart TechOne
